2021 ANNUAL REPORT

The National Children's Cancer Society

Because no family should go through childhood cancer alone.™

MEET SOME OF OUR BRAVE WARRIORS!

MEET CALEB

Neuroblastoma Warrior

For the last five years, 9-year-old Caleb has been battling Neuroblastoma, a rare childhood cancer that generally develops in the adrenal glands. From surgery to remove the tumors to countless rounds of chemotherapy and immunotherapy, the NCCS has supported Caleb and his family with the exhaustive travel costs from their Indiana home to treatment facilities in New York. Fortunately, Caleb's scans have been much more promising in the last year, and he can enjoy just being a kid – baking, creating art and playing piano and ukulele.

Caleb has defied all odds and his family is deeply grateful for the support provided by the NCCS as they navigate the world of childhood cancer and work toward a healthy future.

MEET LILLIAN

Leukemia Warrior

Lillian was regarded by her parents as "the healthy child," never having even a cold or runny nose. She was the picture of perfect health. That all changed when she was just shy of her 2nd birthday. The diagnosis was T-cell Lymphoblastic Leukemia, a fast-growing, aggressive cancer that turned her family's world upside down.

In addition to addressing the cancer itself, treatment complications, side effects, immune system suppression, abnormal organ functions, loss of motor control and brittle bones are just some of the horrific ripple effects from her diagnosis that Lillian and her family have endured.

Lillian's Mother shared her gratitude for support from the NCCS with travel assistance and educational and social support for Lillian and her family. "We are not sure anyone could have done this alone, and we cannot imagine having to survive this season without the love and support of others. NCCS is a tremendous blessing for people during times when the world is crashing in around you and helps shoulder some of the day-to-day struggles of food, gas and bills."

 

Dear Friends,

Despite the challenges presented by the pandemic these last two years, The National Children's Cancer Society (NCCS) continues to make great strides in our unwavering commitment that no family should go through childhood cancer alone. Whether across town or across the country, the "no matter what" approach of the NCCS ensures that we continue to provide the physical, financial and emotional resources for children battling cancer and their families.

One such child is 6-year-old Julia. At 18 months, Julia was diagnosed with bilateral retinoblastoma, cancer of the eye. Travelling from their home in Wisconsin to New York for regular, aggressive treatment, Julia's family has faced many hardships over the last several years, including the significant impact of unexpected travel costs. Julia's mother, Jessica, has expressed her heartfelt thanks for transportation assistance provided by the NCCS: "Saying thank you isn't enough as we cannot even express in words our gratitude." Today, Julia remains strong through ongoing treatments, and doctors are optimistic that she will lead a long, healthy life.

Julia's story, along with so many others, serves as daily inspiration for the mission of NCCS. But we can't do this work alone. With the support of our compassionate donors, we have assisted more than 46,000 children with cancer and distributed over $69,000,000 in financial assistance since the inception of the NCCS. Through our programs, we have reached children in 53 countries across the globe. To date, we have awarded 544 scholarships totaling nearly $2,000,000 to childhood cancer survivors, celebrating the hope of a bright future for our courageous young warriors.

If the last two years have taught us nothing else, it's a spirit of perseverance–the same spirit that is reflected in the children and families that turn to us for help. Thank you for your continued support so that we can all provide a clear path for families navigating the world of childhood cancer, and most importantly, survivorship.

Please stay safe and well,



Mark Slocomb
Chairman of the Board

Mark Stolze
President and Chief Executive Officer

MISSION

The National Children's Cancer Society (NCCS) provides emotional, financial and educational support to children with cancer, their families and survivors.

OVERVIEW

Since its inception, the NCCS **has helped more than 46,000 children** with cancer and their families by **providing over $69 million** in program distributions. The NCCS is a 501(c)(3) non-profit organization that is proud to meet all of the Better Business Bureau's "Standards of Charity Accountability," which includes a comprehensive, in-depth evaluation of charity governance, fundraising practices, solicitations and informational materials. The organization is also a Platinum Participant on GuideStar Exchange,

FY2021 REVENUE ALLOCATION



BECAUSE NO FAMILY SHOULD GO THROUGH CHILDHOOD CANCER ALONE™

Pediatric oncology nurses and social workers at treatment centers across the country refer families to the NCCS. One hundred seventy nine (179) treatment centers referred 1,578 families in need of assistance to the organization this fiscal year.

HOW WE HELP DURING TREATMENT

When a family is facing the tragedy of childhood cancer, the only thing they should have to focus on is getting their child well again. They shouldn't be overwhelmed with the costs of just getting their child to treatment. But, how many of us have a savings plan in place for childhood cancer?

The NCCS offers two programs to ease the financial strain of a childhood cancer diagnosis. Our **Transportation Assistance Fund** alleviates some of the travel expenses incurred to get a child to treatment such as mileage, airfare and lodging when the best place for treatment is away from home.

The **Emergency Assistance Fund** provides an annual stipend to families who have a child who has been inpatient or away from home for an extended period of time. Assistance may be used for many daily expenses families face including mortgage payments, rent, utility bills and other treatment-related costs such as prescriptions and parking.

In addition to the financial impact of childhood cancer, the emotional toll can be devastating. Our **Family Support Program** helps ease the emotional strain that accompanies a childhood cancer diagnosis by providing an NCCS case manager who stands by a family's side from diagnosis through survivorship. These dedicated individuals are specially trained to offer practical and emotional support during difficult times, educate parents and caregivers on how to best advocate for their child and provide referrals when needed.

THE NCCS ASSISTED FAMILIES BATTLING CHILDHOOD CANCER AT THE FOLLOWING PEDIATRIC ONCOLOGY FACILITIES ACROSS THE U.S.

ALABAMA
Children's of Alabama, Birmingham
St. Jude Affiliate Clinic at Huntsville Hospital for Women & Children, Huntsville
USA Children's & Women's Hospital, Mobile

ALASKA
Alaska Pediatric Oncology, Anchorage

ARIZONA
Banner Children's at Desert, Mesa
Banner - University Medical Center, Tucson
Phoenix Children's Hospital, Phoenix

ARKANSAS
Arkansas Children's Hospital, Little Rock
Arkansas Children's Northwest, Springdale

CALIFORNIA
Children's Hospital Los Angeles, Los Angeles
CHOC Children's, Orange
City of Hope, Duarte
Hoffmann Hospice & Palliative Care, Bakersfield
Kaiser Permanente, Fontana
Kaiser Permanente, Los Angeles
Kaiser Permanente, Oakland
Kaiser Permanente, Ontario
Kaiser Permanente, Roseville
Kaiser Permanente, San Diego
Loma Linda University Children's Health, Loma Linda
Loma Linda University Children's Health, San Bernardino
Miller Children's & Women's Hospital, Long Beach
Rady Children's Hospital, San Diego
Rady's Proton Center, San Diego
Stanford Children's Health - CA Pacific Medical Center, San Francisco
Stanford Children's Health - Lucile Packard Children's Hospital Stanford, Palo Alto
Sutter Medical Center, Sacramento
UC Davis Medical Center, Sacramento
UCSF Benioff Children's Hospital, San Francisco
UCSF Benioff Children's Hospital, Oakland
Valley Children's Healthcare, Madera
Ventura County Medical Center, Ventura

COLORADO
Children's Hospital Colorado, Aurora
Rocky Mountain Hospital for Children, Denver

CONNECTICUT
Connecticut Children's, Hartford

DELAWARE
Nemours Children's Hospital, Wilmington

DISTRICT OF COLUMBIA
Children's National, Washington, DC

FLORIDA
AdventHealth for Children, Orlando
Ascension Sacred Heart Hospital, Pensacola
Bascom Palmer Eye Institute, Miami
Golisano Children's Hospital - SW Florida, Ft. Myers
Jackson Health System, Miami
Joe DiMaggio Children's Hospital, Hollywood
Johns Hopkins All Children's Hospital, St. Petersburg
Johns Hopkins All Children's Hospital, Tampa
Kids Cancer Foundation, Loxahatchee
Nemours Children's Health, Jacksonville
Nemours Children's Health System, Orlando
Nicklaus Children's Hospital, Miami
Orlando Health Arnold Palmer Hospital for Children, Orlando
St. Joseph's Children's Hospital, Tampa
St. Mary's Medical Center, West Palm Beach
Sylvester Comprehensive Cancer Center, Miami
Tampa General Hospital, Tampa
UF Health Shands Children's Hospital, Gainesville
Wolfson Children's, Jacksonville

GEORGIA
Children's Healthcare of Atlanta, Atlanta
Children's Healthcare of Atlanta at Egleston, Atlanta
Children's Healthcare of Atlanta at Scottish Rite, Atlanta
Children's Hospital of Georgia, Augusta
Emory Children's Clinic, Atlanta
Memorial Health Dwaine & Cynthia Willett Children's Hospital, Savannah
Atrium Health Navicent, Macon

ILLINOIS
Advocate Children's Hospital, Park Ridge
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
OSF HealthCare Children's Hospital of Illinois, Peoria
St. Jude Midwest Affiliate, Peoria
UChicago Medicine Comer Children's, Chicago

INDIANA
Beacon Children's Hospital, South Bend
Peyton Manning Children's Hospital at Ascension St. Vincent, Indianapolis
Riley Hospital for Children, Indianapolis

IOWA
Blank Children's Hospital, Des Moines
University of Iowa Stead Family Children's Hospital, Iowa City

KANSAS
Wesley Children's Hospital, Wichita

KENTUCKY
Norton Children's Hospital, Louisville
UK HealthCare Kentucky Children's Hospital, Lexington

LOUISIANA
Children's Hospital, New Orleans
LSU Health, Shreveport
Ochsner Medical Center, New Orleans
Our Lady of the Lake Children's Hospital, Baton Rouge
St. Jude Baton Rouge Affiliate Clinic, Baton Rouge

MARYLAND
Johns Hopkins Bloomberg School of Public Health, Baltimore
Johns Hopkins Children's Center, Baltimore

MASSACHUSETTS
Baystate Medical Center, Springfield
Boston Children's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
UMass Memorial Health, Worcester

MICHIGAN
Bronson Children's Hospital, Kalamazoo
Children's Hospital of Michigan, Detroit
Helen DeVos Children's Hospital, Grand Rapids
University of Michigan Medical Center, Ann Arbor

MINNESOTA
Mayo Clinic Hospital, St. Mary's, Rochester
Mayo Eugenio Litta Children's Hospital, Rochester
University of Minnesota Masonic Children's Hospital, Minneapolis

MISSISSIPPI
University of Mississippi Medical Center, Jackson

MISSOURI
Barnes-Jewish Hospital, St. Louis
Children's Hospital, St. Louis
Children's Mercy, Kansas City
Mercy Clinic Children's Cancer and Hematology, St. Louis
SSM Health Cardinal Glennon Children's Hospital, St. Louis
St. Jude Affiliate Clinic, Springfield
Washington University School of Medicine, St. Louis

MONTANA
Montana Children's Medical Center, Kalispell

NEBRASKA
Children's Hospital & Medical Center, Omaha
Nebraska Medical Center, Omaha

NEVADA
Renown Children's Hospital, Reno
Summerlin Hospital Medical Center, Las Vegas
Sunrise Children's Hospital, Las Vegas

NEW HAMPSHIRE
Children's Hospital at Dartmouth-Hitchcock, Lebanon

NEW MEXICO
Presbyterian Hospital, Albuquerque
UNM Children's Hospital, Albuquerque

NEW YORK
Albany Medical Center Hospital, Albany
Cohen Children's Medical Center, New Hyde Park
John R. Oishei Children's Hospital, Buffalo
Memorial Sloan Kettering Cancer Center, New York
NYU Langone Health, New York
NewYork-Presbyterian Morgan Stanley Children's Hospital, New York
Upstate Golisano Children's Hospital, Syracuse

NORTH CAROLINA
Levine Children's Hospital, Charlotte
Mission Hospital, Asheville
UNC Health, Chapel Hill
Vidant Medical Center, Greenville
Wake Forest Baptist Health, Winston-Salem

NORTH DAKOTA
Sanford Medical Center, Bismarck
Sanford Roger Maris Cancer Center, Fargo

OHIO
Akron Children's Hospital, Akron
Cincinnati Children's, Cincinnati
Cleveland Clinic Children's, Cleveland
Dayton Children's, Dayton
Nationwide Children's, Columbus
ProMedica Russell J. Ebeid Children's Hospital, Toledo
University Hospitals Rainbow Babies and Children's, Cleveland

OKLAHOMA
St. Francis Hospital, Tulsa
Oklahoma Children's Hospital, Oklahoma City

OREGON
Doernbecher Children's Hospital, Portland
Randall Children's Hospital at Legacy Emanuel, Portland

PENNSYLVANIA
Children's Hospital of Philadelphia, Philadelphia
Lehigh Valley Reilly Children's Hospital, Allentown
Milton S. Hershey Medical Center, Hershey
St. Christopher's Hospital for Children, Philadelphia
UPMC Children's Hospital of Pittsburgh, Pittsburgh

RHODE ISLAND
Hasbro Children's Hospital, Providence

SOUTH CAROLINA
Prisma Health Greenville Memorial Hospital, Greenville
MUSC Children's Health, Charleston
Sanford Children's Hospital Sioux Falls, Sioux Falls

TENNESSEE
Children's Hospital at Erlanger, Chattanooga
East Tennessee Children's Hospital, Knoxville
Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville
Niswonger Children's Hospital, Johnson City
St. Jude Children's Research Hospital, Memphis
St. Jude Tri Cities Affiliate Clinic, Johnson City
The Children's Hospital at TriStar Centennial, Nashville
Vanderbilt University, Nashville

TEXAS
Children's Medical Center, Dallas
Children's Memorial Hermann Hospital, Houston
Cook Children's Medical Center, Ft. Worth
Covenant Medical Center, Lubbock
Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
El Paso Children's Hospital, El Paso
Baylor Scott & White McLane Children's, Temple
Methodist Children's Hospital, San Antonio
Texas Children's Hospital, Houston
Texas Tech University Health Sciences Center, Amarillo
The University of Texas MD Anderson Cancer Center, Houston

UTAH
Primary Children's Hospital, Salt Lake City

VERMONT
The University of Vermont Children's Hospital, Burlington

VIRGINIA
Children's Hospital of Richmond at VCU, Midlothian
Children's Hospital of The King's Daughters, Norfolk
University Hospital, Charlottesville
Virginia Commonwealth University, Richmond

WASHINGTON
Mary Bridge Children's, Tacoma
Providence Sacred Heart Medical Center & Children's Hospital, Spokane
Seattle Children's, Seattle

WEST VIRGINIA
CAMC Women and Children's Hospital, Charleston
West Virginia University Medicine Children's, Morgantown

WISCONSIN
Children's Wisconsin, Milwaukee
American Family Children's Hospital, Madison

BEYOND THE CURE

Beyond the Cure is the NCCS survivorship program which prepares survivors and their families for life after cancer.

One of the largest issues survivors face are post-treatment physical and cognitive issues known as "late effects." Most survivors will experience one or more late effects in their lifetime which are caused more from the treatment than the disease, itself.

Our **Late Effects After Treatment Tool (LEATT)** is a valuable resource that provides survivors with a private, customized online assessment of potential late effects based on their diagnosis and treatment. The assessment includes important information that can be shared with a survivor's healthcare team throughout their lifetime.

The LEATT was developed in collaboration with NCCS board member, Robert Hayashi, MD, Professor of Pediatrics, Director, Late Effects Clinic, St. Louis Children's Hospital/Washington University School of Medicine.

Beyond the Cure also awards college scholarships to childhood cancer survivors through the **Beyond the Cure Ambassador Scholarship Program.** 58 college-bound childhood cancer survivors around the country received scholarships totaling $203,000 during FY2021.

First-time applicants are required to submit an essay addressing how cancer has affected their lives and future, as well as how they plan to give back to the childhood cancer community.

More than $1.8 million has been distributed to survivors to help them achieve their educational goals. The NCCS is deeply grateful to **Centene Corporation** and the **Engelhardt Family Foundation** for their generous support of the program.

SURVIVORSHIP CONFERENCES

Beyond the Cure co-sponsors survivorship conferences with long term follow-up clinics across the country. Due to the COVID-19 pandemic, only one conference was held in FY21 at Advocate Children's Hospital in Chicago, IL.

EDUCATIONAL PUBLICATIONS

The organization distributed 1,908 free publications during FY2021. The NCCS publication library includes an activity book that provides a creative outlet for patients to learn about themselves and their cancer treatment, coloring books for young children, information for college-bound survivors and in-depth guides for both survivors and their families.

MICHELE HERTLEIN GLOBAL OUTREACH PROGRAM

Michele Hertlein
July 15, 1968 – August 5, 2020

Most childhood cancers can be cured if treated promptly and effectively. However, eighty percent of children diagnosed with cancer in low - and middle - income countries will lose their battle due to a lack of information, early detection and access to effective treatment.

The Michele Hertlein Global Outreach Program addresses the inadequate or nonexistent medical care for children with cancer in underserved countries around the globe, at absolutely no cost to the family.

Over $21 million in donated pharmaceuticals and medical supplies were sent free of charge to 10 pediatric oncology treatment centers, totaling 42 hospitals and their associated clinics in 20 countries this fiscal year.

Since its inception, this unique program has distributed in excess of $438 million in donated pharmaceuticals to 77 facilities in 53 countries, helping to save the lives of an estimated 171,000 children with cancer worldwide.

The program's namesake, Michele Hertlein, worked tirelessly for 24 years to secure and ship donated pharmaceuticals and medical supplies to pediatric treatment centers around the world. Michele lost her own 10-year battle with cancer in 2020 and is dearly missed. She leaves a legacy of compassionate, relentless pursuit to support children and their families in their battle against childhood cancer–NO MATTER WHAT.

WORLDWIDE FACILITY PARTNERS

FRANCE
Groupe Franco-Africain d'Oncologie Pédiatrique

EL SALVADOR
Centro Médico Fundación Ayúdame a Vivir San Salvador

GUATEMALA
Fundación Ayudame a Vivir, Unidad Nacional de Oncologia Pediatrica, Guatemala City

HAITI
Nos Petits Freres et Soeurs, Hospital St. Damien, Port-au-Prince

HONDURAS
Fundación Hondurena para el Niño con Cancer Hospital, Tegucigalpa

LEBANON
Children's Cancer Center of Lebanon (CCCL), Beirut
LAU Medical Center, CHANCE Association, Beirut

MOROCCO
Service d'Hematologie et d'Oncologie Pediatrique, Casablanca

NICARAGUA
MINSA – Hospital Infantil la Mascota, Managua

ZIMBABWE
Children's Cancer Relief – KidzCan Zimbabwe, Harare

CliftonLarsonAllen LLP
CLAconnect.com

INDEPENDENT AUDITORS' REPORT

Board of Directors
The National Children's Cancer Society, Inc.
St. Louis, Missouri

We have audited the accompanying financial statements of The National Children's Cancer Society, Inc. (a nonprofit organization), which comprise the statement of financial position as of September 30, 2021, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the financial statements referred to above present fairly in all material respects the financial position of The National Children's Cancer Society, Inc., as of September 30, 2021, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

CliftonLarsonAllen LLP

CliftonLarsonAllen LLP

St. Louis, Missouri
January 4, 2022

STATEMENT OF FINANCIAL POSITION
SEPTEMBER 30, 2021

ASSETS

CURRENT ASSETS	
Cash	$ 521,961
Accounts Receivable, Net	266,995
Employee Retention Credit Receivable	363,906
Inventory	16,882
Prepaid Expenses and Other Assets	31,998
Total Current Assets	1,201,742
NONCURRENT ASSETS	
Investments	4,875,096
Property and Equipment, Net	5,172
Total NonCurrent Assets	4,880,268
Total Assets	$ 6,082,010

LIABILITIES AND NET ASSETS

CURRENT LIABILITIES	
Accounts Payable	$ 1,059,539
Annuities Payable	17,240
Accrued Expenses	127,975
Unearned Revenue	7,896
Line of Credit	413,288
Total Current Liabilities	1,625,938
LONG-TERM LIABILITIES	
Annuities Payable	101,381
Total Long-Term Liabilities	101,381
NET ASSETS	
Without Donor Restrictions	3,661,074
With Donor Restrictions	693,617
Total Net Assets	4,354,691
Total Liabilities and Net Assets	$ 6,082,010

STATEMENT OF ACTIVITIES
YEAR ENDED SEPTEMBER 30, 2021

	Without Donor Restrictions	With Donor Restrictions	Total
PUBLIC SUPPORT AND REVENUE			
Contributions	$ 7,582,341	$ -	$ 7,582,341
List Rental Income	65,443	-	65,443
Event Revenue	143,637	-	143,637
Less Direct Costs of Events	(5,427)	-	(5,427)
In-Kind Contributions	21,663,575	-	21,663,575
Investment Income	766,801	100,249	867,050
Employee Retention Credit Income	363,906	-	363,906
Paycheck Protection Plan Forgiveness	554,260	-	554,260
Net Assets Released from Restrictions -			
Satisfaction of Program Restrictions	15,113	(15,113)	-
Total Public Support and Revenue	31,149,649	85,136	31,234,785
EXPENSES			
Program Services:			
Division of Patient and Family Services	23,843,608	-	23,843,608
Supplemental Family Support	1,177,069	-	1,177,069
Public Information and Education	259,396	-	259,396
Total Program Services	25,280,073	-	25,280,073
Supporting Services:			
Management and General	783,487	-	783,487
Fundraising	3,636,637	-	3,636,637
Total Supporting Services	4,420,124	-	4,420,124
Total Expenses	29,700,197	-	29,700,197
OTHER INCOME (EXPENSE)			
Change in Value of Annuities	(8,457)	-	(8,457)
NET CHANGE IN NET ASSETS	1,440,995	85,136	1,526,131
Net Assets - Beginning of Year	2,220,079	608,481	2,828,560
NET ASSETS - END OF YEAR	$ 3,661,074	$ 693,617	$ 4,354,691

See accompanying Notes to Financial Statements.

STATEMENT OF FUNCTIONAL EXPENSES
YEAR ENDED SEPTEMBER 30, 2021

	Program Services			Supporting Services		
	Division of Patient and Family Services	Supplemental Family Support	Public Information and Education	Management and General	Fundraising	Total
Aid Grants	$ 21,663,575	$ 1,039,986	$ -	$ -	$ -	$ 22,703,561
Production Services	-	-	-	461,329	3,265,220	3,726,549
Family Services and Education	1,330,957	1,240	2,346	-	-	1,334,543
Salary Expense	373,630	74,446	140,869	174,548	169,417	932,910
Professional Services	86,100	17,155	32,462	40,223	39,040	214,980
Insurance	79,690	15,879	30,046	37,229	36,134	198,978
In-Kind Program Shipping	166,811	-	-	-	-	166,811
Rent and Utilities	38,275	7,626	14,431	17,881	17,355	95,568
Other Expenses	36,948	7,362	13,931	18,010	16,754	93,005
Payroll Taxes	29,310	5,840	11,050	13,692	13,290	73,182
Cause Related Marketing	-	-	-	-	62,277	62,277
Retirement	18,682	3,722	7,044	8,728	8,471	46,647
Telephone	7,232	1,441	2,727	3,378	3,279	18,057
Postage, Shipping, and Handling	4,641	925	1,750	2,168	2,104	11,588
Equipment Rental	3,109	619	1,172	1,452	1,410	7,762
Office Supplies and Services	1,889	376	712	3,789	856	7,622
Direct Costs of Events	-	-	-	-	5,427	5,427
Depreciation Expense	1,492	297	563	697	677	3,726
Meetings and Travel	777	155	293	363	353	1,941
Shipping and Procurement	490	-	-	-	-	490
Total	23,843,608	1,177,069	259,396	783,487	3,642,064	29,705,624
Less: Direct Costs of Events	-	-	-	-	(5,427)	(5,427)
Total Expenses	$ 23,843,608	$ 1,177,069	$ 259,396	$ 783,487	$ 3,636,637	$ 29,700,197

STATEMENT OF CASH FLOWS
YEAR ENDED SEPTEMBER 30, 2021

CASH FLOWS FROM OPERATING ACTIVITIES	
Net Change in Net Assets	$ 1,526,131
Adjustments to Reconcile Net Change in Net Assets to Net Cash Used by Operating Activities	
Paycheck Protection Program Loan Forgiveness	(554,260)
Proceeds from Sales of Contributed Investments	55,510
Depreciation	3,726
Change in Value of Annuities	8,457
Unrealized Gain on Investments	(486,236)
Realized Gain on Investments	(296,350)
(Increase) Decrease in:	
Accounts Receivable	(14,821)
Employee Retention Credit Receviable	(363,906)
Inventory	5,887
Prepaid Expenses and Other Assets	1,253
Increase (Decrease) in:	
Accounts Payable	(381,265)
Annuity Payable	14,161
Accrued Expenses	(66,271)
Unearned Revenue	1,462
Net Cash Used by Operating Activities	(546,522)
CASH FLOWS FROM INVESTING ACTIVITIES	
Purchases of Property and Equipment	(3,973)
Proceeds from Sale of Investments	1,398,206
Purchases of Investments	(1,087,870)
Net Cash Provided by Investing Activities	306,363
CASH FLOWS FROM FINANCING ACTIVITIES	
Net Proceeds on Line of Credit	160,661
Proceeds from Paycheck Protection Program Loan	259,130
Net Cash Provided by Financing Activities	419,791
NET CHANGE IN CASH	179,632
Cash - Beginning of Year	342,329
CASH - END OF YEAR	$ 521,961

See accompanying Notes to Financial Statements.

NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations

The National Children's Cancer Society, Inc. (the Organization) was incorporated in November 1987 to serve children with cancer and their families. Program services are categorized as follows: Division of Patient and Family Services, Supplemental Family Support and Public Information and Education. The Organization provides a Family Support Program, Transportation Assistance Fund, and Emergency Assistance Fund for families with children in treatment, a Beyond the Cure Program for cancer survivors, and a Global Outreach Program.

Basis of Presentation

Financial statement presentation follows the recommendations of the Financial Accounting Standards Board (FASB). The Organization is required to report information regarding its financial position and activities according to two classes of net assets: net assets without donor restrictions and net assets with donor restrictions. As of September 30, 2021, the Organization had $693,617 in net assets with donor restrictions.

Basis of Accounting

The financial statements of the Organization have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).

Concentration of Credit Risk

The majority of the Organization's cash and cash equivalents are maintained at three banks. The bank provides a maximum protection under regulations issued by the Federal Deposit Insurance Corporation. At September 30, 2021, deposits at the bank in excess of federally insured limits were $132,414.

Cash and Cash Equivalents

Cash includes demand deposits and highly liquid financial instruments purchased with original maturities of three months or less. The carrying amount of cash equivalents approximates fair value.

Certain cash balances are required to be held in separate bank accounts in accordance with contractual arrangements.

Accounts Receivable

Receivables consist of amounts due to the Organization related to the direct mail, telemarketing, and royalty programs. Management writes off receivables when it determines that an amount will not be collected and considers all receivables at September 30, 2021 to be collectible. Therefore, no allowance for doubtful accounts is recorded at September 30, 2021. All receivables are considered current at September 30, 2021; therefore, no discount has been recorded.

Investments

In accordance with accounting standards, investments in marketable securities with readily determinable fair values are reported at fair value in the statement of financial position. Unrealized gains and losses are included in the statement of activities.

Inventory

Inventory consists of program literature and patient and family service items and is stated at the lower of cost or net realizable value, determined on the first-in, first out method.

Property and Equipment

Furniture and equipment is recorded at cost. Maintenance and repairs are charged to operations when incurred. Betterments and renewals in excess of $500 are reviewed individually by management and are capitalized.

Donations of furniture and equipment are recorded as support at their estimated fair value. Such donations are reported as without donor restricted support unless the donor has restricted the donated asset to a specific purpose.

Depreciation and amortization are provided on a straight-line basis over the following periods:

Furniture and Fixtures	7 Years
Equipment	3 to 7 Years
Software	3 Years
Leasehold Improvements	7 Years

Compensated Absences

Employees of the Organization are entitled to paid vacation days depending on length of service. Amounts accrued for compensated absences are included in accounts payable and accrued expenses in the accompanying statement of financial position.

NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Contributions

In accordance with accounting standards, contributions received by the Organization are recorded as with donor restriction or without donor restriction support, depending on the existence and nature of any donor restrictions. When a restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. Contributions that are restricted by the donor are reported as increases in net assets without donor restrictions if the restrictions expire within the fiscal year the contributions are recognized.

Annuities Payable

Annuities payable represents an annuity obligation for gift annuities received by the Organization. Gift annuities provide for payment to named annuitants over their lifetimes. The payment is guaranteed by the Organization through an agreement. An annuities payable liability is recorded until the projected termination of the annuity payment obligation based upon the present value of the expected payments over the life expectancy of the annuitants. The current annuity values are valued at fair value. The Organization reviews AFR in determining the discount rate to apply for the present value calculation. A discount rate of 1.0% was applied to determine the liability at September 30, 2021. Fair value at September 30, 2021 is $263,257, while the recorded liability is $118,621.

Unearned Revenue

Unearned revenue consists of payments received in advance that relate to donated items to be sold by a third party in a future period and are deferred and recognized as revenue in the period earned.

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of support, revenues, and expenses during the reporting period, including grant and contract revenues subject to review by applicable funding agencies. Accordingly, actual results could differ from those estimates.

Fair Value Measurements

The Organization measures fair value using a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability. Inputs may be observable or unobservable and refer broadly to the assumptions that market participants would use in pricing the asset or liability. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the reporting entity's own assumptions about the assumptions that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.

The objective of a fair value measurement is to determine the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). Accordingly, the fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The Organization may use valuation techniques consistent with the market, income and cost approaches to measure fair value.

The inputs used to measure fair value are categorized into the following three categories:

Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical investments, such as stocks, corporate and government bonds that the Organization has the ability to access as of the measurement date.

Level 2 - Inputs, other than quoted prices, that are observable for the asset or liability either directly or indirectly, including inputs from markets that are not considered to be active.

Level 3 - – Inputs that are unobservable. Unobservable inputs reflect the Organization's own assumptions about the factors market participants would use in pricing an investment, and is based on the best information available in the circumstances.

Following is a description of the valuation methodologies and inputs used for assets measured at fair value on a recurring basis and recognized in the accompanying statements of financial position, as well as the general classification of such assets and liabilities pursuant to the valuation hierarchy.

Where quoted market prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. Level 1 securities include money market mutual funds, certain mutual funds, and equities. If quoted market prices are not available, then fair values are estimated by using pricing models or quoted prices of securities

NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

with similar characteristics. These Level 2 securities include mortgaged and asset-backed securities, corporate and municipal bonds, U.S. government agencies, hedge funds and managed futures. Inputs used to value Level 2 securities include interest rates for similar debt securities, Treasury obligations with similar maturities and net asset values provided by funds is utilized as a practical expedient. In certain cases where Level 1 or Level 2 inputs are not available, securities are classified within Level 3 of the hierarchy and include hedge funds. The net asset value (or its equivalent) provided by the fund is utilized, as a practical expedient, to determine fair value of these Level 3 investments. The funds are classified as Level 3 if they may not be redeemable in the short-term.

Any transfers in and out of Level 1 (quoted market prices), Level 2 (other significant observable inputs) and Level 3 (significant unobservable inputs) are recognized on the period ending date.

Development Costs

The Organization periodically incurs substantial costs for the continued development of a contributor list. In accordance with U.S. GAAP, the Organization recognizes these costs as they are incurred against operations, even though the contributor lists are expected to provide significant benefit to future periods.

Functional Expense Allocations

The costs of providing various program and other activities of the Organization have been summarized on a functional basis in the statement of functional expenses. Expenses are charged to program services, fundraising or management and general based on actual costs incurred by the program or supportive service, as well as on management's best estimate of time spent in the functional expense categories. Management and general expenses include those expenses that are not directly identifiable with any other specific section but provide for the overall support and direction of the Organization.

Tax Status

The Organization qualifies as a tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code. However, the Organization is liable for federal income taxes on certain unrelated business income.

Management analyzed the tax positions taken by the Organization and concluded that, as of September 30, 2021, there were no uncertain tax positions taken or are expected to be taken. Accordingly, no interest or penalties related to uncertain tax positions have been accrued in the accompanying financial statements.

Change in Accounting Principle

In May 2014, FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606). Subsequent to May 2014, the FASB has issued six ASUs to clarify certain matters related to Topic 606. Topic 606 requires the recognition of revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The updates address the complexity and understandability of revenue recognition and provide sufficient information to enable financial statements users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.

These financial statements reflect the application of ASC 606 guidance beginning in the year ended September 30, 2021. No cumulative-effect adjustment in net assets was recorded as the adoption of ASU 2014-09 did not significantly impact the Organization's reported historical revenue.

Subsequent Events

In preparing these financial statements, the Organization has evaluated events and transactions for potential recognition or disclosure through January 4, 2022, the date the financial statements were available to be issued.

NOTE 2 LIQUIDITY AND AVAILABILITY

Financial assets available for general expenditure, this is, without donor or other restrictions limiting their use, within one year of the statement of financial position date, comprise the following at September 30, 2021:

Cash and Cash Equivalents	$ 521,961
Accounts Receivable	266,995
Investments	4,875,096
Total Current Financial Assets	5,664,052
Less: Net Assets With Donor Restrictions Relating to Current Financial Assets	(693,617)
Financial Assets Available to Meet Cash Needs for General Expenditures Within One Year	$ 4,970,435

The Organization classifies investments as noncurrent assets due to the intended purpose of holding them long-term but could be used as a source of current liquidity. The Organization receives significant contributions without donor restrictions, and are considered for programs which are ongoing, major, and central to its annual operations. Contributions without donor restrictions are to be available to meet cash needs for general expenditures, which include administrative and general expenses, fund raising expenses, and grant commitments expected to be paid in the subsequent year. Annual operations are defined as activities occurring during the Organization's fiscal year. The Organization also has a line of credit with available credit of $2,779,376 that could be used if needed.

NOTE 3 INVESTMENTS

Investments consist of the following at September 30, 2021:

Government and Agency Securities	$ 547,561
Equity Securities	3,365,008
Mutual Funds	962,527
Total Investments	$ 4,875,096

Investment return for the year ended September 30, 2021 is summarized as follows:

Interest and Dividend Income	$ 84,464
Unrealized Gain on Equity Securities	486,236
Realized Gain on Sale of Investments	296,350
Total Investment Gain	$ 867,050

NOTE 4 FAIR VALUE MEASUREMENTS

The Organization uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. For additional information on how the Organization values all other assets and liabilities refer to Note 1 – Organization and Summary of Significant Accounting Policies.

The following table presents the fair value hierarchy for the balances of the assets of the Organization measured at fair value on a recurring basis as of September 30, 2021:

	Total	(Level 1)	(Level 2)	(Level 3)
Government and Agency Bonds	$ 547,561	$ –	$ 547,561	$ –
Equity Securities	3,365,008	3,365,008	–	–
Mutual Funds	962,527	962,527	–	–
Total	$ 4,875,096	$ 4,327,535	$ 547,561	$ –

NOTE 5 NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions at September 30, 2021 consist of:

Purpose Restriction For Cancer Treatment in Minnesota	$ 693,617

Assets released from restrictions for the year ended September 30, 2021 are as follows:

Satisfaction of Purpose Restriction	$ 15,113

NOTE 6 PROPERTY AND EQUIPMENT

Property and equipment consists of the following at September 30, 2021:

Furniture and Fixtures	$ 17,878
Equipment	50,012
Software	298,611
Leasehold Improvements	6,800
Total	373,301
Less: Accumulated Depreciation	(368,129)
Property and Equipment	$ 5,172

Depreciation expense was $3,726 for the year ended September 30, 2021.

NOTE 7 ALLOCATION OF JOINT COSTS

The Organization combines the costs of its joint activities that combine fundraising appeals with other functions, and allocates those costs to their functional classifications. Such costs include printing, caging, donor search, public information, computer expenses, list development, direct mail expense, postage, and production fees. The physical units method is used to allocate these costs. This allocation process is based on lines of print from the documents and scripts used in the joint activities. Each line of print is analyzed and a determination is made as to its purpose. The number of lines for each objective is totaled and weighed against the total number of lines in the document as well as the frequency of use of the document.

The Organization's total joint costs incurred and functional classifications for the year ended September 30, 2021 are as follows:

Functional Classification:	
Program Services	$ 1,334,543
Management and General	461,329
Fundraising	3,265,220
Total Joint Costs	$ 5,061,092
Type of Activity:	
Direct Mail	$ 5,056,507
Telemarketing	4,585
Total Joint Costs	$ 5,061,092

The Organization follows standards for accounting and reporting costs of joint activities that combine fundraising appeals with other functions including definitions for the criteria of purpose, audience, and content. In accordance with the standard, the compensation structure of the joint activity is considered, as well as the target audience of the activity and the content of the information conveyed. If any of the criteria of purpose, audience, and content is not met, all costs of the joint activity are considered fundraising.

NOTE 8 OPERATING LEASES

The Organization leases office space, office equipment, and a vehicle under operating leases. The Organization's office lease has escalating lease payments ranging from $4,760 to $5,170 per month over the remaining term of the lease expiring September 30, 2023.

The future minimum rental payments required under operating leases that have initial or remaining noncancellable lease terms in excess of one year as of September 30, 2021 are as follows:

Year Ending September 30,	Amount
2022	113,097
2023	107,037
Total	$ 220,134

Total rental expense under operating leases with a term in excess of one month was $68,256 for the year ended September 30, 2021.

NOTE 9 RETIREMENT PLAN

The Organization has a defined contribution retirement plan covering substantially all of its employees. Contributions to the plan and related expenses were $46,647 for the year ended September 30, 2021.

NOTE 10 AID GRANTS

The Organization receives and disburses both cash and in-kind grants to individuals and organizations. During the year ended September 30, 2021, the Organization recognized and disbursed $21,663,575 of in-kind contributions, consisting primarily of pharmaceuticals and medical supplies. The grants were recorded at their estimated fair value in the financial statements based on valuations provided by the donors, primarily manufacturers or distributors, and comparison with other industry sources.

NOTE 11 LINE OF CREDIT

The Organization has a Loan Management Account Agreement with a bank which allows the Organization to borrow under a revolving line of credit arrangement. Available credit is subject to borrowing base limitations determined by the bank based upon the market value of pledged securities. Advances under the agreement can be made under variable rate, fixed rate and term advances agreed upon at the time of the advance. Advances are due upon demand. Investments held by Merrill Lynch are pledged as collateral. Available credit under the agreement at September 30, 2021 was $2,779,376. At September 30, 2021, borrowings under the agreement were $413,288, all in principal. The balance is subject to interest at a variable rate of LIBOR plus the spread. The interest rate as of September 30, 2021 is 2.09%.

Cash paid for interest on the line of credit was $7,394 for the year ended September 30, 2021.

NOTE 12 PAYROLL PROTECTION PROGRAM LOAN

On April 13, 2020, and January 20, 2021, the Organization received loans from Triad Bank totaling $295,130 and 259,130 respectively, to fund payroll, rent, utilities, and interest on mortgages and existing debt through the Paycheck Protection Program (the PPP Loan). The PPP Loans bear interest at a fixed rate of 1.0% per annum, have terms of two years, and are unsecured and guaranteed by the U.S. Small Business Administration (SBA). Payment of principal and interest is deferred until the date on which the amount of forgiveness is remitted by the SBA to the lender or, if the Organization fails to apply for forgiveness within 10 months after the covered period, then payment of principal and interest shall begin on that date. These amounts are subject to forgiveness based on compliance with program requirements and approval by the SBA. The covered period from April 17, 2020 to October 2, 2020 for the first loan and January 20, 2021 to July 6, 2021 for the second loan is the time that the business had to spend their PPP Loan funds.

The Organization is following ASC 470, Debt, to account for the initial receipts related to the PPP Loans. On November 2, 2020, the SBA processed the Organization's first PPP Loan forgiveness application and notified Triad Bank the PPP Loan qualified for full forgiveness. Loan proceeds were received by the bank from the SBA on this date. Then, on August 10, 2021, SBA processed the second PPP Loan and notified Triad bank the PPP Loan qualified for full forgiveness. Therefore, the Organization was legally released from the debt of both loans and the loan forgivenesses have been recorded as a gain on extinguishment of debt, which is included in other income during the year ended September 30, 2021.

The SBA may review funding eligibility and usage of funds for compliance with program requirements based on dollar thresholds and other factors. The amount of liability, if any, from potential noncompliance cannot be determined with certainty; however, management is of the opinion that any review will not have a material adverse impact on the Organization's financial position.

NOTE 13 EMPLOYEE RETENTION CREDIT

Grants from the government are recognized when all conditions of such grants are fulfilled or there is reasonable assurance that they will be fulfilled. The Association complied with the conditions of Employee Retention Credit (ERC) funding in the amount of $363,906 in compliance with the program.

Grants related to this program are classified as other income and grants receivable. The Association recognized $363,906 of employee retention credits and grants receivable related to performance requirements being met and costs being incurred in compliance with the program during the year ended September 30, 2021.

NOTE 14 RELATED PARTY TRANSACTIONS

During the year ended September 30, 2021, the Organization received $52,058 in contributions from various members of the board of directors (Directors). In addition, during the year ended September 30, 2021, the Organization received $75,000 from companies in which Directors serve as a director or officer. At September 30, 2021, there were no receivables from related parties. The Organization also did not receive any In-Kind gifts from various board members of the board of directors during the year ended September 30, 2021.

One of the asset custodians is a financial institution for which a member of the board of the National Children's Cancer Society is an officer. The amount paid to the asset custodian during the year ended September 30, 2021 totaled $54,121. The board member was not directly compensated for services provided.

NOTE 15 RISKS AND UNCERTAINTIES

The Organization's assets include investments in various securities which, in general, are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is reasonably possible that changes in risks in the near term would materially affect the amounts reported in the balance sheets and the statements of activities.

The World Health Organization declared the spread of Coronavirus Disease (COVID-19) a worldwide pandemic. The COVID-19 pandemic is having significant effects on global markets, supply chains, businesses and communities. Specific to the Organization, COVID-19 may impact various parts of its 2022 operations and financial results. Management believes the organization is taking appropriate actions to mitigate the negative impact. However, the full impact of COVID-19 is unknown and cannot be reasonably estimated as these events are still developing.



BOARD OF DIRECTORS

Mark Slocomb
Chairman / Vice Chairman

Scott Stringer
Vice Chairman

Sue Engelhardt
Secretary/Treasurer

Mark Stolze
President & CEO

Dr. Timothy Dilg

Michael Gallagher

Tom Guebert

Scott Hammack

Robert Hayashi, M.D.

Brad Hermann

Brad Loos

Jeff Michalski, M.D.

Harry Mueller

Allen T. Smith

The
National
Children’s
Cancer
Society

The National Children's Cancer Society
500 North Broadway, Suite 1850
Saint Louis, MO 63102
thenccs.org